novavax covid vaccine

Order byBest matchMost fresh

FDA, Covid-19 vaccine

Top News

Overview

Impacts

After delay, FDA approves Novavax’s Covid-19 vaccine, but only for older people and those at high risk

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who hav...

· 6d · on MSN

STAT · 16h

FDA gives Covid vaccine manufacturers instructions for next fall’s shot

· 2d · on MSN

Who can get updated COVID vaccines this fall? FDA will OK for high-risk groups, calls for new clinical trials

The FDA plans to limit access to covid vaccines. Here’s why that’s not all bad.

Covid vaccines will soon be required to go through more rigorous trials to ensure that they really are beneficial for people who aren’t at high risk.

MIT Technology Review · 23h

· 5h

Uncertainty loomed as FDA advisors met to discuss this year’s COVID shot

Arizona PBS · 15h

FDA ends routine COVID shots for healthy young Americans

US FDA Advisers to Weigh Composition of COVID Vaccines for 2025-2026

Public health experts say that there is no certainty on which strains are going to be dominant.

· 1d

· 17h

COVID shots should target newer strains of JN.1 variant, US FDA advisers say

· 1d

With vaccine approval process set to change, FDA advisers leave wiggle room in annual Covid-19 shot recommendations

Infectious Disease Advisor2d

FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

20hon MSN

FDA advisers recommend updating COVID shots to JN.1 strain

Moderna (MRNA), and Novavax (NVAX) agree as the FDA advisors recommend targeting JN.1 strain for updated COVID vaccines this fall. Read more here.

4don MSN

RFK Jr. pledged not to upend US vaccine system, but big changes are underway

WASHINGTON — Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by pledging to work within the decades-old federal system for approval and use of vaccines. Yet his regulators are promising big changes that cloud the outlook for what shots might even be available.